A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of EXforge and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment.
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Amlodipine/valsartan (Primary) ; Nifedipine
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms EXAM
- Sponsors Novartis
- 12 Aug 2013 Results published in Advances in Therapy.
- 04 Oct 2012 Primary endpoint 'Diastolic-blood-pressure' has been met.
- 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History